Sponsors (2)
The bill increases transparency, funding, and oversight across drug pricing, public health, and health‑care access—potentially lowering costs and strengthening preparedness—at the cost of higher federal spending and substantial new reporting, compliance, privacy, and implementation burdens that may be passed on to smaller market participants and, ultimately, consumers.
Millions of patients, plan sponsors, and employers will get far more transparent, machine-readable drug- and PBM-pricing data (rebates, net prices, pass-throughs and claims-level information), enabling plans and employers to monitor PBM behavior, negotiate better contracts, and potentially lower out-of-pocket costs.
Significant new and expanded funding for community health centers, workforce programs, maternal/child health, overdose prevention, hospital preparedness, regional labs, and related public‑health grants will strengthen primary care access, clinician recruitment to underserved areas, and emergency response capacity.
Medicare and Medicaid beneficiaries will gain concrete access and consumer protections: improved Medicare Advantage provider-directory accuracy and public ratings, extended telehealth flexibilities (including audio-only for FQHCs/RHCs and hospice payment clarity), streamlined cross‑state HCBS enrollment for certain children, and HDHP telehealth safe harbors—reducing barriers to in‑network care and
All Americans (taxpayers) face increased federal spending and longer‑term budgetary commitments from multiple new or expanded authorizations and appropriations across health, preparedness, and research programs.
States, plans, PBMs, pharmacies, providers, and federal agencies will face substantial new administrative, reporting, IT and compliance burdens to produce, verify, and publish machine‑readable pricing and program data—costs that may be passed to patients or employers via higher premiums or reduced services.
Detailed, frequent disclosure requirements and expanded surveillance (including wastewater programs and machine-readable public datasets) raise privacy, proprietary, and civil‑liberties concerns for patients, providers, small communities, and commercial actors if safeguards and redaction rules are insufficient.
Based on analysis of 36 sections of legislative text.
Reforms Medicaid enrollment, Medicare payment timing, PBM transparency/rules for Part D and group plans, boosts funding for community health and preparedness, and strengthens pediatric drug pathways and telehealth HDHP rules.
Introduced March 6, 2025 by Ronald Lee Wyden · Last progress March 6, 2025
Makes wide-ranging changes across federal health policy to strengthen oversight, reporting, and funding for Medicaid, Medicare, Part D/Pharmacy Benefit Managers (PBMs), public health preparedness, and pediatric drug development. It creates a streamlined Medicaid enrollment path for certain out-of-state providers for youth, requires greater PBM transparency and new limits on PBM remuneration in Part D and group plans, mandates Medicare Advantage provider directory accuracy reporting, adjusts timing and formulas for hospital payment programs, and funds community health centers, teaching health centers, and preparedness laboratories. Affecting patients, providers, plans, states, and federal agencies, the bill adds new reporting and enforcement tools (including civil money penalties for PBM reporting failures), authorizes multiple years of funding for prevention and health workforce programs, advances pediatric cancer trial and labeling rules at FDA, and provides a temporary telehealth deductible safe harbor for high-deductible health plans. Many provisions have staggered effective dates (some months to years after enactment) and impose new data, compliance, and administrative responsibilities on states, plans, PBMs, hospitals, and federal agencies.